Roche opens Boston research centre as Sanfilippo gene therapy enters clinical use

A Stat News biotech round-up notes that a gene therapy has received FDA approval for Sanfilippo syndrome (mucopolysaccharidosis type III A, MPS IIIA), a rare autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme heparan sulphate sulphamidase, encoded by SGSH. The approval was reported alongside news of Roche expanding its research footprint in Boston.

Sanfilippo syndrome type A is among the most common and severe subtypes of MPS III. It is characterised by progressive neurodegeneration in childhood, with onset typically in the first years of life and no previously approved disease-modifying treatment. An AAV-based gene therapy delivering a functional copy of SGSH has been the subject of clinical investigation for several years; regulatory approval marks a significant development for affected families and rare-disease researchers.

This item overlaps in subject matter with the Genetic Current cluster published on 18 September 2026 covering the Ultragenyx FDA approval for Sanfilippo syndrome type A. The Stat News item references the same approval in passing within a wider biotech digest, and does not provide additional primary findings. It is included here only to note the Roche research centre news context; readers seeking detail on the Sanfilippo approval are directed to the 18 September cluster.